rais price target ew follow unveil
result increas convict upsid
forecast ew us ou tavr unit associ benefit bottom line
rubber met road low-risk opportun offici unlock
ew remain top large-cap pick
ew sapien superior surgeri one year low-risk trial
consid ew latest data sapien good realist possibl think
result acceler convers savr tavr low-risk patient
popul come month year find compon analysi especi
compel particularli statist signific superior demonstr tavr
savr stroke one year death disabl stroke one year mani investor fear
tavr would show meaning benefit savr harder endpoint like stroke
would instead reli exclus differ rehospit consid softer
endpoint given abil game drive superior outcom overal didnt
happen although tavr sapien show statist signific superior
savr all-caus mortal demonstr favor trend compar savr
low absolut rate one year patient trial tavr arm also spent
fewer day hospit initi savr group median day vs
day tavr patient discharg home oppos
remain hospit special care set major remain question
whether durabl tavr valv compar savr valv note
protocol specifi clinic echocardiograph follow-up least
year help provid answer
whose result publish saturday random patient
center march octob patient sever aortic stenosi
low risk death surgeri underw either tavr ew sapien valv
surgic aortic valv replac savr commerci avail surgic valv
patient follow least one year follow-up plan
patient studi primari endpoint composit all-caus mortal stroke
rehospit one year tavr sapien show statist superior
reduct event vs savr specif patient tavr group experienc
death caus stroke rehospit one year compar patient
savr arm repres absolut differ
group yield p-valu less noninferior equal
superior respect individu compon primari endpoint rate
all-caus mortal one year tavr savr
rate stroke one year tavr savr rate
rehospit one year tavr savr addit
rate death disabl stroke one year tavr savr
figur page compil result tavr savr endpoint
day one year signific differ group
major vascular complic new perman pacemak insert moder sever
paravalvular regurgit notabl one year rate new perman pacemak
baselin pacemak patient exclud one year tavr sapien
vs savr repres patient respect mdt evolut
risk trial perman pacemak implant one year tavr vs
pleas see page report import disclosur
base outperform rate belief sustain ew high-single-digit
double-digit top-lin growth along double-digit ep growth trajectori driver
compani includ tavr market leadership age global elderli popul shift
aortic stenosi risk curv tavr rais tavr awar among patient
expect last year fda ce mark approv sapien intermedi risk aid
upsid trial prove favor believ ew share continu valu
premium median forward price-to-earnings multipl compani large-cap peer churn
centera sapien ultra ce launch
intermedi risk market develop
wake surtavi data readout
updat mitral program timelin
maintain market share
us tavr market
strong adopt sapien high-risk/
inoper patient us
continu success roll-out sapien
intermedi risk
top-lin growth acceler
ew mitral program develop faster
top-lin growth deceler
expect
ew lead medic devic compani manufactur heart valv repair
product replac repair diseas defect heart compani also provid
hemodynam monitor system cardiovascular function measur hospit
set headquart irvin california ew oper roughli countri
employe world-wide compani found edward
laboratori acquir baxter spun baxter earli
ew sale product world-wide posit
rais think multipl expans well-deserv low-risk
superior hand
increas price target ew follow
increas convict upsid forecast ew ou tavr
unit along associ benefit compani bottom line target partli
base discount cash flow analysi valu base savr critic tavr
busi new target impli price-to-earnings multipl appli adjust
ep estim repres signific premium median price-to-earnings multipl
ew large-cap medic devic peer group roughli exclud ew
anticip meaning out-performance ew cours result
favor consensu estim revis therefor consid multipl choic
remain optimist ew experi acceler growth tavr franchis
year sever driver strengthen util trend deeper penetr
intermediate-risk indic follow stellar low-risk data contribut
new centera ultra valv increas level low-risk creep
fda approv later bigger boost low risk actual
fda approv indic think ew extrem well-posit
transcathet mitral opportun valid coapt data
believ ew stock momentum sustain continu strong
world-wide ultra centera trend addit favor updat mitral
tricuspid program along initi contribut pascal europ begin
moreov think grand slam data make tavr therapi
choic across sever symptomat aortic stenosi risk class rubber met
road low-risk opportun offici unlock enhanc
investor sentiment regard ew alreadi uniqu profil sustain multi-year
figur endpoint ew partner trial sapien
death stroke dayson yeardeath disabl strokeal strokeall-caus cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market setback develop tmvr
product prevent commerci fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock corp corp secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
